Compare Charles River Laboratories Intl. Inc (CRL) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Expedia Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $299.03 (market cap $14.23B), while Expedia Group Inc trades at $269.73 (market cap $32.42B). The key difference: Expedia Group Inc is far larger — about 2.3× Charles River Laboratories Intl. Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Expedia Group Inc for 48 Days on average.
| CRL | EXPE | |
|---|---|---|
Market Cap | $14.23B | $32.42B |
Volume | 1,176,885 | 1,940,671 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $339.13 |
52-Week Low | $149.93 | $188.51 |
Typical Hold Time | 33 Days | 48 Days |
Enterprise Value | $17.06B | $30.98B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, amid a bearish technical signal and recent news-driven volatility. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $14.73B in 2025, and robust profitability margins. Recent layoffs and competitive threats from AI travel agents have pressured sentiment, but analyst consensus remains largely positive with a $335.06 price target.
The outlook balances solid financial health and attractive valuation against near-term competitive and execution risks. Upside potential exists if Expedia navigates AI disruption and sustains booking growth, but investor caution is warranted given technical weakness and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
